All News
Day 1 Report from EULAR 2026
The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day.
Read Article
The pain that inflammation does not explain in SpA and PsA
Clinicians often come across the scenario of a patient with well-controlled spondyloarthritis where the ASDAS in the low disease activity range, CRP normalised, joints clinically quiet. However, the patient returns to the clinic still reporting significant pain. Their rheumatologist adjusts the biological, waits, returns. The pain persists.
Read Article
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
Over 70% of patients with PsA struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question: are clinical gains in PsA driven purely by weight reduction, or do these agents carry intrinsic anti-inflammatory properties? EULAR 2026 offered six abstracts that together illuminate, without fully resolving, this question.
Read Article
COMPARE Trial: CAR-T Cell Rx in 6 refractory active CCP+ RA pts (failed 4-7 prior b/tsDMARDs). After lymphodepletion w/ CTX + fludarabine, B cells depleted w/ neutropenia. Significant drops in CCP, RF, and DAS28, but at wk 12 only 50% ACR 20 response. Encouraging data but not https://t.co/txm32NkOKW
Dr. John Cush RheumNow ( View Tweet)
And we are on!
A full house for #EULAR2026 Opening ceremony highlighting @eular_org initiatives in the field of research, education and patient empowerment and a call “better care leading to better lives” by president Xenofon Baraliakos
@RheumNow https://t.co/zTQUFcjXBI
Aurelie Najm AurelieRheumo ( View Tweet)
It’s that time of year again! 🎉
Delighted to once again be joining the @RheumNow faculty to bring you the highlights from #EULAR2026 in London!
@bella_mehta
@JihaRheum
@AurelieRheumo
@Janetbirdope
@Nellziade
@RHEUMarampa
@synovialjoints
@Yuz6Yusof https://t.co/WvhpYJJNUk
Mrinalini Dey DrMiniDey ( View Tweet)
ACPA and the Transition from Arthralgia to Rheumatoid Arthritis
Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for https://t.co/pCaYdEg1gZ
Dr. John Cush RheumNow ( View Tweet)
"the further I look back, the further I can see the future"
Dennis McGonagle quoting Winston Churchill to describe his approach to understanding What is New in PsA at #EULAR2026
@eular_org @RheumNow https://t.co/ayInzzb9lO
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2026 OP0125 It’s a case of “teamwork makes the dream work!” Instead of an index to capture heterogeneity in #Sjogren activity, the NECESSITY validated using data from 16 RCTs that a new composite tool, STAR has high sensitivity & specificity. Vital for use in RCTs @RheumNow https://t.co/ftx1uBP11A
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
📈 Do SIJ lesions progress in #axSpA?
DESIR cohort (n=649, 10yrs):
Yes, slowly, but bDMARDs reduce erosion progression
#OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍 Best imaging outcome for #axSpA structural change?
SPACE cohort (n=332): MRI-SIJ fat lesions most sensitive to change
#OP0103 #EULAR2026 @RheumNow https://t.co/His1BGYmEW
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🖥️ Can MRI-based synthetic CT detect spinal progression in #axSpA?
COPECARE (n=25, 1yr): sCT matches ldCT with no radiation
#OP0104 #EULAR2026 @RheumNow https://t.co/pe9wSMXXZQ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍 Is #axSpA overdiagnosed locally?
IMPROVE-axSpA prosp study (n=969):
Yes!
Only 54% locally confirmed centrally
#OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍Can early TNFi beat step-up csDMARDs in pSpA?
SPARTACUS RCT (n=97) says YES
60% vs 33% remission at 24 wks
#EULAR2026 @rheumnow #OP0107 https://t.co/1odtcRdTLQ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
💉 IXE+TZP beat IXE alone in obese PsA?
YES - TOGETHER-PsA RCT
33.5% vs 20.4% ACR50 at week 36 in 271 patients
OP069 #EULAR2026 @RheumNow
@DrLauraCoates @AlexisOgdie https://t.co/orvAe38alc
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🥗 Does diet improve PsA?
DIPSA RCT: Mediterranean/DASH/Standard all improved DAPSA in 92pts
Weight loss drove outcomes
OP070 #EULAR2026 @RheumNow https://t.co/k5y7bvDbDQ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA:
Females ⬆️ dse act (asdas,basdai) ⬆️enthesitis scores, S/TJCts
Males ⬆️rate of xray prog(msasss)
Sex diffs exist in SpA
Need for sex-specific mgt
AbsOP0101 @Rheumnow #EULAR2026 https://t.co/qiNzDFh08v
sheila RHEUMarampa ( View Tweet)
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't spend hours sorting through hundreds of abstracts; RheumNow will do it for you.
Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty as they break down the https://t.co/eAPV6h5FAn
Links:
Dr. John Cush RheumNow ( View Tweet)
♂♀ Does sex matter in #axSpA long-term?
GESPIC (n=525,10y):
Yes! ♂ less symptoms but 2x more spinal progression
#OP0101 #EULAR2026 @RheumNow https://t.co/znFXWyrfZl
Nelly ZIADE 🍀 Nellziade ( View Tweet)
